Bottom line
FHLC vs SWHFX: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and SWHFX (Schwab Health Care Fund) share a meaningful slice of their top holdings — about 76% by weight.
But FHLC is far broader, holding 337 positions to 80 for SWHFX, so beyond the top names it adds exposure SWHFX doesn't have.
FHLC is cheaper at 0.084% vs 0.8% — a difference of $72 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +6.5% for SWHFX (reporting dates differ).
Updated Nov 19, 2026
FHLC vs SWHFX side by side
| FHLC | SWHFX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Fidelity | Schwab |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 0.8% |
| Annual cost per $10k | $8.4 | $80 |
| 10-yr cost on $10k (prospectus) | $108 | $990 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +2.6% | +15.9% |
| 5-yr return (annualized) | +7.2% | +6.5% |
| 10-yr return (annualized) | +8.8% | +8.1% |
| Best quarter | +16.4% | +15.3% |
| Worst quarter | −13.1% | −12.1% |
| Net assets (fund) | $3.3B | $642.3M |
| Number of holdings | 337 | 80 |
| Portfolio turnover | 3% | 41% |
| Returns as of | Nov 30, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | SWHFX | Difference |
|---|---|---|---|
| 2024 | +2.6% | +0.1% | +2.5% |
| 2023 | +2.5% | +0.7% | +1.8% |
| 2022 | −5.5% | −4.7% | −0.8% |
| 2021 | +20.4% | +23.3% | −2.9% |
| 2020 | +18.1% | +12.9% | +5.3% |
| 2019 | +21.9% | +17.6% | +4.3% |
| 2018 | +5.5% | +4.0% | +1.5% |
| 2017 | +23.3% | +20.2% | +3.1% |
| 2016 | −3.3% | −4.4% | +1.0% |
Source: Fund prospectus bar charts
Holdings overlap
17 of FHLC's top 25 holdings also appear in SWHFX's top 25.
| Holding | FHLC | SWHFX |
|---|---|---|
| Eli Lilly & Co | 13.35% | 13.92% |
| Johnson & Johnson | 8.93% | 6.94% |
| AbbVie Inc | 6.42% | 5.81% |
| UnitedHealth Group Inc | 5.44% | 4.74% |
| Merck & Co Inc | 4.66% | 4.98% |
| Thermo Fisher Scientific Inc | 3.09% | 2.16% |
| Amgen Inc | 3.00% | 2.58% |
| Abbott Laboratories | 2.66% | 1.60% |
| Gilead Sciences Inc | 2.34% | 3.24% |
| Bristol-Myers Squibb Co | 1.93% | 2.44% |
| Danaher Corp | 1.80% | 1.47% |
| Vertex Pharmaceuticals Inc | 1.76% | 1.89% |
| Stryker Corp | 1.62% | 2.11% |
| Medtronic PLC | 1.59% | 2.29% |
| Elevance Health Inc | 1.19% | 1.45% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
FAQ
What is the difference between FHLC and SWHFX?
Which is cheaper, FHLC or SWHFX?
Should I own both FHLC and SWHFX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.